The Nomination Committee for the 2024 Annual General Meeting comprises the following members:

• Per Arwidsson, appointed by Arwidsro,
• Håkan Lagerberg, appointed by Mastan AB, and
• Peter Zonabend, Chairman of the Board of Vivesto.

Per Arwidsson has been appointed Chairman of the Nomination Committee.

Vivesto’s Annual General Meeting will be held on 23 May 2024.

Shareholders who wish to submit proposals to the Nomination Committee for the 2024 Annual General Meeting may send them by e-mail to nomination@vivesto.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.

For further information, please contact:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a portfolio of projects with the potential to offer new treatment options for cancer patients with high unmet medical needs. The cancer program Cantrixil is being developed in the indications bladder cancer and blood cancer, and the veterinary oncology product Paccal Vet (paclitaxel micellar) is being developed for the treatment of malignant melanoma and hemangiosarcoma in dogs.

Vivesto has experience in developing drugs from the preclinical phase, through clinical development to regulatory approval. Vivesto's longest-developed program, Apealea® (paclitaxel micellar), has received market approval in the EU for the treatment of adult patients suffering from a first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, in combination with carboplatin.

Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.